Transcription factor GATA-1 and Down syndrome leukemogenesis

References

• Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003; 17: 1738–1752
   PubMed Web of Science ®Google Scholar
• Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005; 105: 4187–4190
   PubMed Web of Science ®Google Scholar
• Daser A, Rabbitts T H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 2004; 18: 965–974
   PubMed Web of Science ®Google Scholar
• Song W J, Sullivan M G, Legare R D, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166–175
   PubMed Web of Science ®Google Scholar
• Wechsler J, Greene M, McDevitt M A, Anastasi J, Karp J E, Le Beau M M, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148–152
   PubMed Web of Science ®Google Scholar
• Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 2003; 361: 1617–1620
   PubMed Web of Science ®Google Scholar
• Hitzler J K, Cheung J, Li Y, Scherer S W, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101: 4301–4304
   PubMed Web of Science ®Google Scholar
• Mundschau G, Gurbuxani S, Gamis A S, Greene M E, Arceci R J, Crispino J D. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003; 101: 4298–4300
   PubMed Web of Science ®Google Scholar
• Rainis L, Bercovch D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102: 981–986
   PubMed Web of Science ®Google Scholar
• Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003; 102: 2960–2968
   PubMed Web of Science ®Google Scholar
• Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480–2489
   PubMed Web of Science ®Google Scholar
• Tsai S F, Martin D I, Zon L I, D'Andrea A D, Wong G G, Orkin S H. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 1989; 339: 446–451
   PubMed Web of Science ®Google Scholar
• Evans T, Felsenfeld G. The erythroid-specific transcription factor Eryf1: a new finger protein. Cell 1989; 58: 877–885
   PubMed Web of Science ®Google Scholar
• Martin D I, Orkin S H. Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1. Genes Dev 1990; 4: 1886–1898
   PubMed Web of Science ®Google Scholar
• Trainor C D, Omichinski J G, Vandergon T L, Gronenborn A M, Clore G M, Felsenfeld G. A palindromic regulatory site within vertebrate GATA-1 promoters requires both zinc fingers of the GATA-1 DNA-binding domain for high-affinity interaction. Mol Cell Biol 1996; 16: 2238–2247
   PubMed Web of Science ®Google Scholar
• Newton A, Mackay J, Crossley M. The N-terminal zinc finger of the erythroid transcription factor GATA-1 binds GATC motifs in DNA. J Biol Chem 2001; 276: 35794–35801
   PubMed Web of Science ®Google Scholar
• Tsang A P, Visvader J E, Turner C A, Fujiwara Y, Yu C, Weiss M J, et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997; 90: 109–119
   PubMed Web of Science ®Google Scholar
• Welch J J, Watts J A, Vakoc C R, Yao Y, Wang H, Hardison R C, et al. Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 2004; 104: 3136–3147
   PubMed Web of Science ®Google Scholar
• Pevny L, Simon M C, Robertson E, Klein W H, Tsai S F, D'Agati V, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349: 257–260
   PubMed Web of Science ®Google Scholar
• Simon M C, Pevny L, Wiles M V, Keller G, Costantini F, Orkin S H. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet 1992; 1: 92–98
   PubMed Web of Science ®Google Scholar
• Weiss M J, Keller G, Orkin S H. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8: 1184–1197
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Browne C P, Cunniff K, Goff S C, Orkin S H. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA 1996; 93: 12355–12358
   PubMed Web of Science ®Google Scholar
• Terajima M, Nemoto Y, Obinata M. Inducible expression of erythroid-specific mouse glycophorin gene is regulated by proximal elements and locus control region-like sequence. J Biochem (Tokyo) 1995; 118: 593–600
   PubMed Web of Science ®Google Scholar
• Minie M, Clark D, Trainor C, Evans T, Reitman M, Hannon R, et al. Developmental regulation of globin gene expression. J Cell Sci Suppl 1992; 16: 15–20
   PubMedGoogle Scholar
• Gregory T, Yu C, Ma A, Orkin S H, Blobel G A, Weiss M J. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999; 94: 87–96
   PubMed Web of Science ®Google Scholar
• Rylski M, Welch J J, Chen Y Y, Letting D L, Diehl J A, Chodosh L A, et al. GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol 2003; 23: 5031–5042
   PubMed Web of Science ®Google Scholar
• Zon L I, Youssoufian H, Mather C, Lodish H F, Orkin S H. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci USA 1991; 88: 10638–10641
   PubMed Web of Science ®Google Scholar
• Munugalavadla V, Dore L C, Tan B L, Hong L, Vishnu M, Weiss M J, et al. Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation. Mol Cell Biol 2005; 25: 6747–6759
   PubMed Web of Science ®Google Scholar
• McDevitt M A, Shivdasani R A, Fujiwara Y, Yang H, Orkin S H. A ‘knockdown’ mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997; 94: 6781–6785
   PubMed Web of Science ®Google Scholar
• Takahashi S, Onodera K, Motohashi H, Suwabe N, Hayashi N, Yanai N, et al. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. J Biol Chem 1997; 272: 12611–12615
   PubMed Web of Science ®Google Scholar
• Pan X, Ohneda O, Ohneda K, Lindeboom F, Iwata F, Shimizu R, et al. Graded levels of GATA-1 expression modulate survival, proliferation, and differentiation of erythroid progenitors. J Biol Chem 2005; 280: 22385–22394
   PubMed Web of Science ®Google Scholar
• Shimizu R, Kuroha T, Ohneda O, Pan X, Ohneda K, Takahashi S, et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 2004; 24: 10814–10825
   PubMed Web of Science ®Google Scholar
• Rosenbauer F, Wagner K, Kutok J L, Iwasaki H, Le Beau M M, Okuno Y, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36: 624–630
   PubMed Web of Science ®Google Scholar
• Cook W D, McCaw B J, Herring C, John D L, Foote S J, Nutt S L, et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 2004; 104: 3437–3444
   PubMed Web of Science ®Google Scholar
• Rosenbauer F, Koschmieder S, Steidl U, Tenen D G. Effect of transcription-factor concentrations on leukemic stem cells. Blood 2005; 106: 1519–1524
   PubMed Web of Science ®Google Scholar
• Visvader J E, Elefanty A G, Strasser A, Adams J M. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J 1992; 11: 4557–4564
   PubMed Web of Science ®Google Scholar
• Visvader J, Adams J M. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993; 82: 1493–1501
   PubMed Web of Science ®Google Scholar
• Pevny L, Lin C S, D'Agati V, Simon M C, Orkin S H, Costantini F. Development of hematopoietic cells lacking transcription factor GATA = 1. Development 1995; 121: 163–172
   PubMed Web of Science ®Google Scholar
• Shivdasani R A, Fujiwara Y, McDevitt M A, Orkin S H. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965–3973
   PubMed Web of Science ®Google Scholar
• Vyas P, Ault K, Jackson C W, Orkin S H, Shivdasani R A. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999; 93: 2867–2875
   PubMed Web of Science ®Google Scholar
• Muntean A G, Crispino J D. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 2005; 106: 1223–1231
   PubMed Web of Science ®Google Scholar
• Stachura D L, Chou S T, Weiss M J. An early block to erythro-megakaryocytic development conferred by loss of transcription factor GATA-1. Blood 2006; 107: 87–97
   PubMed Web of Science ®Google Scholar
• Nichols K E, Crispino J D, Poncz M, White J G, Orkin S H, Maris J M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24: 266–270
   PubMed Web of Science ®Google Scholar
• Mehaffey M G, Newton A L, Gandhi M J, Crossley M, Drachman J G. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001; 98: 2681–2688
   PubMed Web of Science ®Google Scholar
• Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001; 98: 85–92
   PubMed Web of Science ®Google Scholar
• Freson K, Matthijs G, Thys C, Marien P, Hoylaerts M F, Vermylen J, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet 2002; 11: 147–152
   PubMed Web of Science ®Google Scholar
• Yu C, Niakan K K, Matsushita M, Stamatoyannopoulos G, Orkin S H, Raskind W H. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100: 2040–2045
   PubMed Web of Science ®Google Scholar
• Balduini C L, Pecci A, Loffredo G, Izzo P, Noris P, Grosso M, et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004; 91: 129–140
   PubMed Web of Science ®Google Scholar
• Del Vecchio G C, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol 2005; 114: 113–116
   PubMed Web of Science ®Google Scholar
• Calligaris R, Bottardi S, Cogoi S, Apezteguia I, Santoro C. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci USA 1995; 92: 11598–11602
   PubMed Web of Science ®Google Scholar
• Crispino J D. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 2005; 16: 137–147
   PubMed Web of Science ®Google Scholar
• Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 1992; 9: 139–149
   PubMed Web of Science ®Google Scholar
• Zipursky A. Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003; 120: 930–938
   PubMed Web of Science ®Google Scholar
• Zipursky A, Rose T, Skidmore M, Thorner P, Doyle J. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol 1996; 13: 81–87
   PubMed Web of Science ®Google Scholar
• Gamis A S, Hilden J M. Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia. J Pediatr Hematol Oncol 2002; 24: 2–5
   PubMed Web of Science ®Google Scholar
• Taub J W. Relationship of chromosome 21 and acute leukemia in children with Down syndrome. J Pediatr Hematol Oncol 2001; 23: 175–178
   PubMed Web of Science ®Google Scholar
• Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512–524
   PubMed Web of Science ®Google Scholar
• Yang H Y, Evans T. Distinct roles for the two cGATA-1 finger domains. Mol Cell Biol 1992; 12: 4562–4570
   PubMed Web of Science ®Google Scholar
• Visvader J E, Crossley M, Hill J, Orkin S H, Adams J M. The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line. Mol Cell Biol 1995; 15: 634–641
   PubMed Web of Science ®Google Scholar
• Blobel G A, Simon M C, Orkin S H. Rescue of GATA-1-deficient embryonic stem cells by heterologous GATA-binding proteins. Mol Cell Biol 1995; 15: 626–633
   PubMed Web of Science ®Google Scholar
• Weiss M J, Yu C, Orkin S H. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol 1997; 17: 1642–1651
   PubMed Web of Science ®Google Scholar
• Shimizu R, Takahashi S, Ohneda K, Engel J D, Yamamoto M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J 2001; 20: 5250–5260
   PubMed Web of Science ®Google Scholar
• Hitzler J K, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20
   PubMed Web of Science ®Google Scholar
• Kuhl C, Atzberger A, Iborra F, Nieswandt B, Porcher C, Vyas P. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol 2005; 25: 8592–8606
   PubMed Web of Science ®Google Scholar
• Li Z, Godinho F J, Klusmann J H, Garriga-Canut M, Yu C, Orkin S H. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613–619
   PubMed Web of Science ®Google Scholar
• Grass J A, Boyer M E, Pal S, Wu J, Weiss M J, Bresnick E H. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA 2003; 100: 8811–8816
   PubMed Web of Science ®Google Scholar
• Letting D L, Chen Y Y, Rakowski C, Reedy S, Blobel G A. Context-dependent regulation of GATA-1 by friend of GATA-1. Proc Natl Acad Sci USA 2004; 101: 476–481
   PubMed Web of Science ®Google Scholar
• Pal S, Cantor A B, Johnson K D, Moran T B, Boyer M E, Orkin S H, et al. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci USA 2004; 101: 980–985
   PubMed Web of Science ®Google Scholar
• Ikonomi P, Rivera C E, Riordan M, Washington G, Schechter A N, Noguchi C T. Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. Exp Hematol 2000; 28: 1423–1431
   PubMed Web of Science ®Google Scholar
• Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355–1360
   PubMed Web of Science ®Google Scholar
• Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994; 18: 163–171
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Abella E, Krischer J P, Wiley J, Inoue S, Harris M, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210–2214
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Yeager A M, Chang M N, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428–1434
   PubMed Web of Science ®Google Scholar
• Lange B J, Kobrinsky N, Barnard D R, Arthur D C, Buckley J D, Howells W B, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998; 91: 608–615
   PubMed Web of Science ®Google Scholar
• Gamis A S, Woods W G, Alonzo T A, Buxton A, Lange B, Barnard D R, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 2003; 21: 3415–3422
   PubMed Web of Science ®Google Scholar
• Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128: 797–804
   PubMed Web of Science ®Google Scholar
• Kojima S, Sako M, Kato K, Hosoi G, Sato T, Ohara A, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000; 14: 786–791
   PubMed Web of Science ®Google Scholar
• Athale U H, Razzouk B I, Raimondi S C, Tong X, Behm F G, Head D R, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727–3732
   PubMed Web of Science ®Google Scholar
• Taub J W, Huang X, Matherly L H, Stout M L, Buck S A, Massey G V, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999; 94: 1393–1400
   PubMed Web of Science ®Google Scholar
• Taub J W, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005; 44: 33–39
   PubMed Web of Science ®Google Scholar
• Ge Y, Stout M L, Tatman D A, Jensen T L, Buck S, Thomas R L, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005; 97: 226–231
   PubMed Web of Science ®Google Scholar
• Frost B M, Gustafsson G, Larsson R, Nygren P, Lonnerholm G. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome. Leukemia 2000; 14: 943–944
   PubMed Web of Science ®Google Scholar
• Zwaan C M, Kaspers G J, Pieters R, Hahlen K, Janka-Schaub G E, van Zantwijk C H, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002; 99: 245–251
   PubMed Web of Science ®Google Scholar
• Ge Y, Jensen T L, Matherly L H, Taub J W. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non – Down syndrome megakaryocytic leukemia cell lines. Blood 2003; 101: 1551–1557
   PubMed Web of Science ®Google Scholar
• Whitlock J A, Sather H N, Gaynon P, Robison L L, Wells R J, Trigg M, et al. Clinical characteristics and outcome of children with down syndrome and acute lymphoblastic leukemia: a children's cancer group study. Blood 2005; 106: 4043–4049
   PubMed Web of Science ®Google Scholar
• Shimamoto T, Ohyashiki K, Ohyashiki J H, Kawakubo K, Fujimura T, Iwama H, et al. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995; 86: 3173–3180
   PubMed Web of Science ®Google Scholar
• Ge Y, Jensen T L, Stout M L, Flatley R M, Grohar P J, Ravindranath Y, et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004; 64: 728–735
   PubMed Web of Science ®Google Scholar
• Galmarini C M, Mackey J R, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875–890
   PubMed Web of Science ®Google Scholar
• Ge Y, Dombkowski A A, Lafiura K M, Tatman D, Yedidi R S, Stout M L, et al. Differential gene expression, GATA1 target genes and the chemotherapy sensitivity of down syndrome megakaryocytic leukemia. Blood 2005, prepublished online; DOI 10.1182/blood-2005-06-2219
   Web of Science ®Google Scholar
• Ishikawa J, Kaisho T, Tomizawa H, Lee B O, Kobune Y, Inazawa J, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995; 26: 527–534
   PubMed Web of Science ®Google Scholar
• Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 583–591
   PubMed Web of Science ®Google Scholar